Humanized IgG1 anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes, depleting these cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis; spares CD20− plasma cells and hematopoietic stem cells.
Humanized IgG1 anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis, while sparing CD20-negative plasma cells and hematopoietic stem cells.
The anti-CD20 antibody binds CD20 on B cells and induces killing via antibody-dependent cellular cytotoxicity (through Fc gamma receptor–bearing effector cells), complement-dependent cytotoxicity, and apoptosis, depleting CD20+ cells.
A bispecific T‑cell engager antibody (DLL3×CD3) administered intravenously that binds DLL3 on tumor cells and CD3 on T cells to redirect/activate cytotoxic T cells and induce tumor lysis.
Intravenous bispecific antibody that binds DLL3 on tumor cells and CD3 on T cells, forming a cytolytic synapse to redirect and activate T cells independent of MHC, leading to perforin/granzyme-mediated lysis of DLL3-expressing neuroendocrine tumor cells.
Bispecific T‑cell engager binds DLL3 on tumor cells and CD3 on T cells, forming a cytolytic synapse; activated T cells release perforin and granzymes to lyse DLL3‑expressing cells.
Autologous ROR1-targeted chimeric antigen receptor (CAR) T-cell therapy; engineered patient T cells expressing an anti-ROR1 CAR (with CD3ζ and co-stimulatory domains) administered after lymphodepletion to mediate immune cytotoxicity against ROR1-positive tumor cells.
Autologous T cells engineered to express an anti-ROR1 chimeric antigen receptor (with CD3ζ and co-stimulatory domains). After lymphodepletion and infusion, CAR engagement of ROR1 on tumor cells triggers T-cell activation, proliferation, cytokine release, and immune-mediated cytotoxic killing of ROR1-positive tumor cells independent of native TCR recognition.
Anti-ROR1 CAR T cells bind ROR1 on target cells and, upon CAR activation, induce cytotoxicity via T-cell effector functions (perforin/granzyme release and death-receptor pathways).
A KLK2×CD3 T-cell–redirecting bispecific antibody that binds KLK2 on prostate tumor cells and CD3 on T cells to trigger TCR-mediated cytotoxicity.
Bispecific antibody that binds KLK2 on prostate tumor cells and CD3 on T cells, redirecting T cells to form an immune synapse and induce TCR-mediated activation and cytotoxic lysis of KLK2-expressing cancer cells.
Bispecific antibody links CD3 on T cells to KLK2 on tumor cells, forming an immune synapse and activating T cells to kill KLK2+ cells via perforin/granzyme-mediated cytolysis.
A PSMA×CD28 costimulatory bispecific antibody that binds PSMA on tumor cells and CD28 on T cells to deliver costimulatory signals and enhance T-cell activation in PSMA-positive settings.
PSMA×CD28 costimulatory bispecific antibody that binds PSMA on tumor cells and CD28 on T cells to provide CD28-mediated costimulation, enhancing T-cell activation and redirecting cytotoxicity toward PSMA-positive tumor cells.
The bispecific links CD28 on T cells to PSMA on tumor cells, providing CD28 costimulation that activates T cells and redirects them to kill PSMA+ cells via CTL-mediated cytotoxicity (e.g., perforin/granzyme).